The Emerging Role of Liquid Biopsy in Gastric Cancer
Authors:
Open Access
- 13 May 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2108
Abstract
(1) Background: Liquid biopsy (LB) is a novel diagnostic method with the potential of revolutionizing the prevention, diagnosis, and treatment of several solid tumors. The present paper aims to summarize the current knowledge and explore future possibilities of LB in the management of metastatic gastric cancer. (2) Methods: This narrative review examined the most recent literature on the use of LB-based techniques in metastatic gastric cancer and the current LB-related clinical trial landscape. (3) Results: In gastric cancer, the detection of circulating cancer cells (CTCs) has been recognized to have a prognostic role in all the disease stages. In the setting of localized disease, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) qualitative and quantitative detection have the potential to inform on the risk of cancer recurrence and metastatic dissemination. In addition, gastric cancer-released exosomes may play an essential part in metastasis formation. In the metastatic setting, the levels of cfDNA show a positive correlation with tumor burden. There is evidence that circulating tumor microemboli (CTM) in the blood of metastatic patients is an independent prognostic factor for shorter overall survival. Gastric cancer-derived exosomal microRNAs or clonal mutations and copy number variations detectable in ctDNA may contribute resistance to chemotherapy or targeted therapies, respectively. There is conflicting and limited data on CTC-based PD-L1 verification and cfDNA-based Epstein–Barr virus detection to predict or monitor immunotherapy responses. (4) Conclusions: Although preliminary studies analyzing LBs in patients with advanced gastric cancer appear promising, more research is required to obtain better insights into the molecular mechanisms underlying resistance to systemic therapies. Moreover, validation and standardization of LB methods are crucial before introducing them in clinical practice. The feasibility of repeatable, minimally invasive sampling opens up the possibility of selecting or dynamically changing therapies based on prognostic risk or predictive biomarkers, such as resistance markers. Research is warranted to exploit a possible transforming area of cancer care.Keywords
This publication has 121 references indexed in Scilit:
- Up-regulation of Ago2 expression in gastric carcinomaMedical Oncology, 2013
- Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transitionBMC Cancer, 2012
- Tumors of the gastroesophageal junction have intermediate prognosis compared to tumors of the esophagus and stomach, but share the same clinical determinantsOncology Letters, 2011
- Circulating Tumor Cells as a Window on Metastasis Biology in Lung CancerThe American Journal of Pathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancerCancer Science, 2010
- Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activationDigestive and Liver Disease, 2009
- Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer PatientsGastroenterology, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinibBritish Journal of Cancer, 2006